Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024
PRINCETON, N.J., Oct. 04, 2024 (GLOBE NEWSWIRE) --Amicus Therapeutics(Nasdaq: FOLD), today announced that three posters highlighting its development program for Pompe disease will be included at the29th Annual Congress of the World Muscle Societybeing held October 8-12, 2024 in Prague, Czechia.
Poster Session: Pompe Disease
Abstract Title:Cipaglucosidase alfa + miglustat in late-onset Pompe disease: two non-ambulatory patients switching from high-dose, high-frequency alglucosidase alfa(Poster #657P)
- Presenter:Barry J. Byrne, MD, PhD, University of Florida, Gainesville, FL, U.S.A.
- Poster Session:Friday, October 11, 3:45 – 4:45 p.m. CET
- Location:Forum Hall, The Prague Congress Centre
Abstract Title:Post-baseline outcomes of the UK Early Access to Medicines Scheme registry for cipaglucosidase alfa plus miglustat in late-onset Pompe disease(Poster #670P)
- Presenter:Mark Roberts, MD, Salford Royal NHS Foundation Trust, Greater Manchester Neurosciences Centre, Manchester, U.K.
- Poster Session:Friday, October 11, 3:45 – 4:45 p.m. CET
- Location:Forum Hall, The Prague Congress Centre
Abstract Title:Miglustat: a first-in-class enzyme stabilizer for late-onset Pompe disease(Poster #671P)
- Presenter:Tahseen Mozaffar,MD, Department of Neurology, University of California, Irvine, CA, U.S.A.
- Poster Session:Friday, October 11, 3:45 – 4:45 p.m. CET
- Location:Forum Hall, The Prague Congress Centre
For more information on the WMS 2024 Annual Congress, please visitwww.wms2024.com
About Amicus TherapeuticsAmicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website atwww.amicusrx.com, and follow onXandLinkedIn.
CONTACTS:
Investors:Amicus TherapeuticsAndrew FaughnanVice President, Investor Relationsafaughnan@amicusrx.com(609) 662-3809
Media:Amicus TherapeuticsDiana MooreHead of Global Corporate Communicationsdmoore@amicusrx.com(609) 662-5079
FOLD–G
